

ANTIBIOTIC SUSCEPTIBILITIES AND β -LACTAMASE PRODUCTION OF *MORAXELLA CATARRHALIS* ISOLATES FROM ZAGREB, CROATIA

Branka Bedenić and Jasmina Vraneš

Department of Microbiology, Andrija Štampar School of Public Health, School of Medicine, University of Zagreb, Zagreb, Croatia

SUMMARY – *Moraxella catarrhalis*, a commensal of the nasopharynx, has been recognized with increasing frequency as a potential pathogen in respiratory tract infections. The β -lactamase production in *Moraxella catarrhalis*, first described in 1977, has been ever more frequently reported in many countries of the world. However, there have been no such reports from Croatia so far. The aim of this study was to investigate antibiotic susceptibilities and β -lactamase production in *Moraxella catarrhalis* isolates from Croatia. Fifty *Moraxella catarrhalis* strains were collected from various clinical specimens at Zagreb University Children's Hospital during the 1990-1992 period. Antibiotic susceptibilities to a wide range of antibiotics were determined by the broth microdilution method according to NCCLS. In all strains, β -lactamases were detected by the disk chromogenic substrate (nitrocefin) test. The prevalence of β -lactamase positive strains in the study period was 100%. No resistance to amoxicillin/clavulanate, cephalexin, ceftibuten, tetracycline, erythromycin, azithromycin and chloramphenicol was observed. In all strains, the activity of amoxicillin was strongly enhanced in the presence of clavulanic acid. Older cephalosporins were equally active, however, the third generation cephalosporin ceftibuten showed significantly lower minimal inhibitory concentrations compared with older compounds. Among non β -lactam antibiotics, tetracycline and erythromycin showed similar activity. Azithromycin had a markedly stronger inhibitory activity in comparison with erythromycin and tetracycline. According to our results, amoxicillin combined with clavulanic acid should be the antibiotic of choice for the treatment of infections caused by β -lactamase positive isolates of *Moraxella catarrhalis*. Oral cephalosporins, tetracycline, macrolides or azithromycin could be an option too.

Key words: *Moraxella-Branhamella catarrhalis* – drug effects; Antiinfective agents – pharmacology; Respiratory tract infections – microbiology; Beta-lactamases – biosynthesis; Croatia

Introduction

Moraxella (M.) catarrhalis, a commensal of the nasopharynx, has been recognized with increasing frequency as a potential pathogen in respiratory tract infections¹⁻². It is an important causative agent of lower respiratory tract infections, otitis media and sinusitis³⁻⁴. *M. catarrhalis* is fully capable of causing systemic diseases such as septicemia

and meningitis in immunocompromised host⁵. These organisms have been transferred from the genus *Neisseria*⁶. The β -lactamase production in *M. catarrhalis*, first described in 1977⁷, has been ever more frequently reported in many countries of the world, e.g., the Netherlands^{1,8}, Sweden⁹, United Kingdom¹⁰, Finland¹¹, Italy¹², Germany¹³, United States^{14,15}, Canada¹⁶, Japan¹⁷, Hong-Kong, South Korea¹⁸ and China¹⁹. There have been no reports on the frequency of β -lactamase production in *M. catarrhalis* from Croatia so far.

There are three types of β -lactamases described: BRO-1, BRO-2 and BRO-3 with similar substrate profiles, isoelectric focusing patterns and sensitivity to inhibitors²⁰⁻²². They all are plasmid mediated, hydrolyze carbenicillin,

Correspondence to: Assist. Prof. Branka Bedenić, M.D., Ph.D., Department of Microbiology, Andrija Štampar School of Public Health, School of Medicine, University of Zagreb, Rockefellerova 4, HR-10000 Zagreb, Croatia

E-mail: branka.bedenic@zg.htnet.hr

Received November 12, 2004, accepted ??, 2004

cefalor and methicillin (but not cloxacillin) as rapidly as benzylpenicillin²¹, and are strongly susceptible to inhibition by clavulanate²³⁻²⁶. BRO β -lactamases are transferable from one strain to another by transconjugation due to plasmid location of the encoding gene²⁷.

BRO β -lactamase positive isolates of *M. catarrhalis* are usually resistant to penicillin, amoxicillin, ampicillin and carbenicillin but are susceptible to a combination of amoxicillin and clavulanic acid^{28,29}, oral and parenteral cephalosporins^{30,31}, carbapenems³², macrolides, tetracyclines, chloramphenicol^{33,34} and fluoroquinolones³⁴⁻³⁶.

β -lactamases of *M. catarrhalis* are produced in small amounts and are located in periplasmic space²⁶. The most frequently used test for routine laboratory detection of this enzyme is the chromogenic (nitrocefin) test³⁷. Enzymes can also be detected by acidimetric and iodometric procedures, however, they are more laborious and time consuming³⁷. The reduced zone diameter around penicillin disk can predict the presence of β -lactamase³⁸. Amoxicillin combined with clavulanic acid (coamoxiclav) is the antibiotic of choice for the treatment of infections caused by lactamase positive strains of *M. catarrhalis*³⁹.

There are only a few reports on the characterization of β -lactamases in *M. catarrhalis* from Croatia^{40,41}. The aim of this study was to investigate antibiotic susceptibilities and β -lactamase production in *M. catarrhalis* isolates from Croatia.

Materials and Methods

Bacteria

During the 1990-1992 period, 50 penicillin resistant *M. catarrhalis* strains were collected at Zagreb University Children's Hospital from various clinical specimens (nasopharyngeal swab, middle ear fluid, sputum, bronchoaspirates). The bacteria were identified by conventional biochemical tests.

Detection of β -lactamases

β -Lactamases were detected by the commercially available chromogenic cephalosporin disk β -lactamase test containing nitrocefin as substrate (Cefinase disks; BBL Microbiology Systems, Cockeysville, MD). The test was repeated with crude enzyme preparations. Fifty μ l of nitrocefin solution (500 mg/L) were mixed with unpurified enzyme sample from each strain. The test was considered positive if the yellow substrate color turned red⁸.

Minimal inhibitory concentrations

Minimal inhibitory concentrations (MIC) of ampicillin, amoxicillin, amoxicillin/clavulanate, cephalixin, cefuroxime, cefadroxil, cefprozil, ceftibuten, tetracycline, erythromycin and azithromycin were determined by a twofold microdilution technique using microtiter plates and Mueller-Hinton broth inoculated with 10^5 CFU/ml^{42,43}. The tested range of antibiotic concentrations was 0.015-128 mg/L. Clavulanic acid was added to amoxicillin in a fixed concentration of 4 mg/L. The antibiotic powders were provided by the following manufacturers: ampicillin, amoxicillin, clavulanate, cephalixin, cefuroxime, tetracycline, erythromycin, azithromycin and chloramphenicol from Pliva, Zagreb, Croatia; cefadroxil and cefprozil from Bristol Myers Squibb, Zagreb, Croatia; and ceftibuten was kindly provided by Prof. Ellen Stobbering (Maastricht University Hospital, Maastricht, The Netherlands). The concentrations of antibiotics which inhibited 50% and 90% of the strains (MIC₅₀ and MIC₉₀) were calculated. Two reference strains, *M. catarrhalis* Ravasio and *M. catarrhalis* 1908, were used as quality control strains for MIC determination. The strains were kindly provided by Dr Christine Cooper (SmithKline Beecham Laboratories, Surrey, UK).

Characterization of β -lactamases

Strains were grown in Brain-Heart infusion broth at 37 °C with shaking and harvested during late log phase. The cells were pelleted by centrifugation at 4 °C, washed twice in 0.1 M phosphate buffer (pH, 7.0), and resuspended in 1/50 of the original volume. After sonication in ice-bath, the cellular debris were removed by centrifugation at 14 000 rpm for 30 min at 4 °C. The crude cellular extract was stored at -20 °C⁸.

The crude β -lactamase extracts were used to evaluate their ability to break down β -lactam antibiotics (ampicillin, cephalixin, cefuroxime, ceftibuten) by a microbiologic method. Antimicrobial disks were impregnated with crude extract from different isolates. The inhibition zones produced by them and by nonimpregnated disks against *E. coli* ATCC 25922 were compared. Reduction of the inhibition zone with the impregnated disk was considered as evidence for β -lactamase activity against the respective antimicrobial agent⁴⁴.

Results

Detection of β -lactamases

In all strains, β -lactamases were detected with both nitrocefin tests.

Prevalence of β -lactamase positive *M. catarrhalis* strains

The prevalence of β -lactamase positive *M. catarrhalis* strains was 100% (50/50).

Antibiotic susceptibilities

Antibiotic susceptibilities are shown in Table 1. MIC ranges for various antibiotics were as follows: ampicillin 1-32 mg/L; amoxicillin 4-32 mg/L; amoxicillin combined with clavulanic acid 0.015-0.5 mg/L; cephalexin 1-16 mg/L; cefuroxime 0.5-32 mg/L; cefprozil and cefadroxil 0.12-32 mg/L; ceftibuten 0.015-1 mg/L; tetracycline and erythromycin 0.015-0.5 mg/L; azithromycin <0.015-0.25 mg/L; and chloramphenicol 0.06-1 mg/L. The concentrations of particular antibiotics necessary to inhibit 50% of the strains were as follows: azithromycin 0.015 mg/L; erythromycin 0.06 mg/L; tetracycline, amoxicillin + clavulanic acid and ceftibuten 0.12 mg/L; chloramphenicol 0.25 mg/L; cefprozil and cefadroxil 1 mg/L; cefuroxime 2 mg/L; cephalexin and ampicillin 4 mg/L; and amoxicillin 8 mg/L. The concentrations of particular antibiotics necessary to inhibit 90% of the strains were as follows: azithromycin 0.12 mg/L; erythromycin, tetracycline and amoxicillin + clavulanic

acid 0.25 mg/L; ceftibuten and chloramphenicol 1 mg/L; cefadroxil 4 mg/L; cefprozil, cefuroxime, cephalexin and ampicillin 16 mg/L; and amoxicillin 32 mg/L. Eighty percent (40/50) of the strains were resistant to amoxicillin, 78% (39/50) to ampicillin, 4% (2/50) to cefadroxil, and 2% (1/50) to cefuroxime and cefprozil. No resistance to cephalexin, ceftibuten, tetracycline, erythromycin, azithromycin and chloramphenicol was observed. In all strains, the activity of amoxicillin was strongly enhanced in the presence of clavulanic acid. Older cephalosporins were equally active, however, the third generation cephalosporin ceftibuten displayed significantly lower MICs compared with older compounds. Among non β -lactam antibiotics tetracycline and erythromycin showed similar activity. Azithromycin had a markedly stronger inhibitory activity in comparison with erythromycin and tetracycline.

Characterization of β -lactamases

Crude β -lactamase extracts from *M. catarrhalis* strains antagonized the activities of disks containing ampicillin (10 μ g). The enzymes did not affect the inhibition zones around cephalosporin disks.

Discussion

The prevalence of β -lactamase positive strains (100%) in Croatia is equivalent to that in Japan¹⁸ and higher than that in the United States (92%)¹⁵, Canada (89%)⁴⁵, Far East

Table 1. Minimal inhibitory concentrations (MIC) of *Moraxella catarrhalis*; concentrations necessary to inhibit 50% and 90% of isolates and percentage of resistant strains according to NCCLS

Antibiotic and resistance breakpoint*	MIC range (mg/L)	MIC ₅₀	MIC ₉₀	Number and percentage of resistant strains
Ampicillin (≥ 4)	1-32	4	16	39/50 (78%)
Amoxicillin (≥ 8)	4-32	8	32	40/50 (80%)
Amoxicillin/clavulanate ($\geq 8/4$)	0.015-0.5	0.12	0.25	0/50 (0%)
Cephalexin (≥ 32)	1-16	4	16	0/50 (0%)
Cefuroxime (≥ 32)	0.5-32	2	16	1/50 (2%)
Cefprozil (≥ 32)	0.12-32	1	16	1/50 (2%)
Cefadroxil (≥ 32)	0.12-32	1	4	2/50 (4%)
Ceftibuten (≥ 32)	0.015-1	0.12	1	0/50 (0%)
Tetracycline (≥ 8)	0.015-0.5	0.12	0.25	0/50 (0%)
Erythromycin (≥ 8)	0.015-0.5	0.06	0.25	0/50 (0%)
Azithromycin (≥ 8)	<0.015-0.25	0.015	0.12	0/50 (0%)
Chloramphenicol (≥ 8)	0.06-1	0.25	1	0/50 (0%)

* Breakpoints for *Haemophilus* were used.

(97.6%)¹⁸, Italy (84%)¹², Finland (96%)¹¹, the Netherlands (39%)⁸ and United Kingdom (90.8%)¹⁰. All strains were found to possess a β -lactamase that was easily detectable due to its extracellular location. Contrary to β -lactamases from Enterobacteriaceae with *M. catarrhalis*, there is no need to release the enzymes from the cells by sonication because of the lack of permeability barrier. The enzymes from all strains were strongly inhibited by clavulanate. The wide range of MICs for ampicillin and amoxicillin alone and in combination with clavulanate could be attributed to variable levels of enzyme production by *M. catarrhalis* strains. The substrate profile of the enzymes was typical for penicillinase type of β -lactamases. They did not hydrolyze significantly cephalosporin substrates although the MICs for cephalosporins are generally lower in β -lactamase negative strains, as reported elsewhere^{8,10}. In our collection, there were no β -lactamase negative strains to compare their MICs with those from β -lactamase positive ones.

The results of the susceptibility tests were in concordance with the results reported by other investigators^{8,10,15,17,31}. The β -lactamase positive strains of *M. catarrhalis* are generally susceptible to all antibiotics except for unprotected penicillins. In order to prevent the emergence of antibiotic resistant isolates, the rational use of antimicrobials and monitoring of the antibiotic resistance of respiratory pathogens will be required.

According to our results, amoxicillin combined with clavulanic acid should be the antibiotic of choice for the treatment of infections caused by β -lactamase positive isolates of *M. catarrhalis*. Oral cephalosporins could also be an option. In case of allergy to β -lactam antibiotics tetracycline, macrolides or azithromycin could be administered. Chloramphenicol should be avoided because of its toxicity.

References

1. STOBBERINGH EE, WUNDERINK M, PHILIPS M, HOUBEN A. *Branhamella catarrhalis*: β -lactamase production and sensitivity to oral antibiotics, including new cephalosporins. J Antimicrob Chemother 1987;20:765-70.
2. NINANE G, JOLY J, PIOT P, KRAYTMAN H. *Branhamella (Neisseria) catarrhalis* as pathogen. Lancet 1977;11:149.
3. JOHNSON MA, DREW WL, ROBERTS M. *Branhamella catarrhalis* – a lower respiratory tract pathogen? J Clin Microbiol 1981;13:1066-9.
4. BLUESTONE CD. Otitis media and sinusitis in children. Role of *Branhamella catarrhalis*. Drugs 1986;31(Suppl 3):132-41.
5. ELIASSON I. β -Lactamases in respiratory tract bacteria. Characterization of β -lactamases in *Branhamella catarrhalis*. Doctoral dissertation. Lund, Sweden: University of Lund., 1990:27-44.
6. CATLIN BW. Transfer of the organism named *Neisseria catarrhalis* to *Branhamella* genus. Int J Syst Bacteriol 1970;20:155-9.
7. MALMWALL BE, BRORSON JE, JOHNSON J. *In vitro* sensitivity to penicillin V and β -lactamase production of *Branhamella catarrhalis*. J Antimicrob Chemother 1977;3:374-5.
8. STOBBERINGH EE, DAVIES B, VAN BOVEN CPA. *Branhamella catarrhalis*: antibiotic sensitivities and β -lactamases. J Antimicrob Chemother 1984;13:55-64.
9. ELIASSON I, KAMMEE C, PRELLNER K. β -Lactamase production in the upper respiratory tract flora. Eur J Clin Microbiol 1986;5:507-12.
10. FUNG CP, POWEL M, SEYMOUR A, YUAN M, WILLIAMS JD. The antimicrobial susceptibility of *Moraxella catarrhalis* isolated in England and Scotland. J Antimicrob Chemother 1992;30:47-55.
11. MANNINEN R, HUOVINEN P, NISSINEN A, Finnish Study Group for Antimicrobial Resistance. Increasing antimicrobial resistance in *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Moraxella catarrhalis* in Finland. J Antimicrob Chemother 1997;40:387-92.
12. NICOLLETTI G, BLANDINO G, CACANO F, FRISCIA O, SCHIOTO AM, SPEZIALE A. The Italian Epidemiological Survey 1997-1999 Antimicrobial susceptibility data of *Haemophilus influenzae*, *Haemophilus parainfluenzae* and *Moraxella catarrhalis* in Italy. Int J Antimicrob Agents 2002;20:263-8.
13. SCHMITZ FJ, BEECKA, PERDIKOULI M, BOOS M, MAYEER S, SCHEURING S, KOHRER K, VERHOFF J, FLUIT AC. Production of BRO- β -lactamases and resistance to complement in European *Moraxella catarrhalis* isolates. J Clin Microbiol 2002;40:1546-8.
14. JORGENSEN JH, DOERN GV, MAHER LA, HOWELAW, REDDING JS. Antimicrobial resistance among respiratory isolates of *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Streptococcus pneumoniae* in the United States. Antimicrob Agents Chemother 1990;34:2075-80.
15. DOERN GV, BRUEGGEMANN AB, PIERCE G, HOGAN T, PRESTON-HOLLEY H Jr, RAUCH A. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of *Moraxella catarrhalis* in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40:2884-6.
16. ZHANEL GG, PALATNICKI, NICHOL KA, LOW DE, HOBAN DJ, CROSS Study Group. Antimicrobial resistance in *Haemophilus influenzae* and *Moraxella catarrhalis* in respiratory tract isolates of the Canadian Respiratory Organisms Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003;47:1875-81.
17. NISHI J, YOSHINAGA K, TOKUDA K, MASUDA K, MASUDA R, KAMENOSONO A, MANAGO K, MIYATA K. Oral antimicrobial susceptibilities of *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* isolated from Japanese children. Int J Antimicrob Agents 2002;20:130-5.
18. INOUE M, YONG-LEE N, HONG SW, LEE K, FELMINGHAM D. PROTEKT 1999-2000: a multicentre study of the antibiotic susceptibility of respiratory tract pathogens in Hong-Kong, Japan and South Korea. Int J Antimicrob Agents 2004;23:44-51.

19. XIAOTIAN Z, YUPU C. β -Lactamase producing *Branhamella catarrhalis* in Beijing, China. *Pediatr Infect Dis J* 1988;7:744.
20. LABIA R, BARTHELEMY M, LE BOUGUENNEC CB, HOI-DANG VAN AB. Classification of β -lactamases from *Branhamella catarrhalis* in relation to penicillinases produced by other bacteria species. *Drugs* 1986;31(Suppl 3):40-7.
21. WALLACE RJ, STEINGRUBE VA, NASH DR, HOLLIS DG, FLANAGAN C, BROWN BA, LABIDI A, WEAVER RE. BRO β -lactamases of *Branhamella catarrhalis* and *Moraxella* subgenus *Moraxella*, including evidence for chromosomal β -lactamase transfer by conjugation in *B. catarrhalis*, *M. nonliquefaciens* and *M. lacunata*. *Antimicrob Agents Chemother* 1989;33:1845-54.
22. CHRISTENSEN JJ, KEIDING J, SCHUMACHER H, BRUUN B. Recognition of a new *Branhamella catarrhalis* β -lactamase - BRO-3. *J Antimicrob Chemother* 1991;28:774-5.
23. COOPER CE, SLOCOMBE B, WHITE AR. Effect of low concentrations of clavulanic acid on the *in vitro* activity of amoxicillin against β -lactamase producing *Branhamella catarrhalis* and *Haemophilus influenzae*. *J Antimicrob Chemother* 1990;26:371-80.
24. FARMER T, READING C. β -Lactamases of *Branhamella catarrhalis* and their inhibition by clavulanic acid. *Antimicrob Agents Chemother* 1982;21:506-8.
25. SLOCOMBE B. Inhibition of β -lactamases in *Branhamella catarrhalis*. *Drugs* 1986;31(Suppl 3):79-81.
26. FARMER T, READING C. Inhibition of β -lactamases of *Branhamella catarrhalis* by clavulanic acid and other inhibitors. *Drugs* 1986;31(Suppl 3):70-8.
27. KAMME C, ELIASSON I, KNUTSTON BK, VANG M. Plasmid-mediated β -lactamase in *Branhamella catarrhalis*. *Drugs* 1986;31(Suppl 3):55-63.
28. COOPER CE, SLOCOMBE B, WHITE AR. Activity of amoxicillin/clavulanic acid against β -lactamase producing *Branhamella catarrhalis* and *Haemophilus influenzae*. Abstract PB7-6. 14th International Congress of Microbiology, Manchester, 1986.
29. FERNANDEZ-ROBLAS R, JIMENEZ-ARRIERO M, RODRIGUEZ-TUDELA JL, SORIANO F. *In vitro* activity of amoxicillin/clavulanic acid and five other oral antibiotics against clinical isolates of *Haemophilus influenzae* and *Branhamella catarrhalis*. *J Antimicrob Chemother* 1988;22:867-72.
30. FUNG CP, YEO SF, LIVERMORE DM. Susceptibility of *Moraxella catarrhalis* to β -lactam antibiotics in relation to β -lactamase pattern. *J Antimicrob Chemother* 1994;33:215-22.
31. DOERN GV, SIEBERS KG, HALLICK LM, MORSE SA. Antibiotic susceptibility of β -lactamase-producing strains of *Branhamella (Neisseria) catarrhalis*. *Antimicrob Agent Chemother* 1980;17:24-9.
32. ALVAREZ S, JONES M, HOLTSCRAWB, GUARDERAS J, BERK S. *In vitro* susceptibilities and β -lactamase production of 53 clinical isolates of *Branhamella catarrhalis*. *Antimicrob Agents Chemother* 1985;27:646-7.
33. YOURASSOWSKYE, van der LINDEN MP, LISMONT MJ, CROKAERT F, GLUPCZYNSKI Y. Rate of bactericidal activity for *Branhamella catarrhalis* of a new macrolide, CP-62,993 compared with that of amoxicillin-clavulanic acid. *Chemotherapy* 1988;34:191-4.
34. KADRY AA, FOU DA SI, ELKHIZZI NA, SHIBL AM. Correlation between susceptibility and BRO type enzyme of *Moraxella catarrhalis* strains. *Int J Antimicrob Agents* 2003;22:532-6.
35. YOURASSOWSKY E, VAN DER LINDEN MP, LISMONT MJ, CROKAERT F, GLUPCZYNSKI Y. Rate of bactericidal activity for *Branhamella catarrhalis* of a feroxacin compared with that of amoxicillin-clavulanic acid. *J Antimicrob Chemother* 1988;22(Suppl D):43-7.
36. GUNDERSON SM, HAYES RA, QUINN JP, DANZIGER LH. *In vitro* pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*. *Antimicrob Agents Chemother* 2004;48:203-8.
37. DOERN GV, TUBERT TA. Detection of β -lactamase activity among clinical isolates of *Branhamella catarrhalis* with six different β -lactamase assays. *J Clin Microbiol* 1987;25:1380-3.
38. LUMAN I, WILSON RW, WALLACE RJ, NASH DR. Disk-diffusion susceptibility of *Branhamella catarrhalis* and relationship of β -lactam zone size to β -lactamase production. *Antimicrob Agents Chemother* 1986;30:774-6.
39. THORNLEY PE, AITKEN JM, NICHOL GM, SLEVIN NJ. Amoxicillin-clavulanic acid combination in bronchopulmonary infection due to β -lactamase producing *Branhamella catarrhalis*. Preliminary report. *Drugs* 1986;31(Suppl 3):113-4.
40. BEDENIĆ B, ŽAGAR Ž. Increased β -lactamase activity in *Branhamella catarrhalis* after exposure to amoxicillin and clavulanic acid. *J Chemother* 1994;6:383-7.
41. BEDENIĆ B, ŽAGAR Ž. Influence of amoxicillin and clavulanic acid on β -lactamase production of *Branhamella catarrhalis*. In: Abstracts of the 6th International Congress on Infectious Diseases, Prague, 1994:132.
42. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th Ed. Approved standard M7-A5. Wayne, Pennsylvania: NCCLS, 2000.
43. DOERN GV, JONES RN. Antimicrobial susceptibility testing of *Haemophilus influenzae*, *Branhamella catarrhalis* and *Neisseria gonorrhoeae*. *Antimicrob Agent Chemother* 1988;32:1747-53.
44. MARTINEZ-MARTINEZ L, HERNANDEZ-ALLES S, ALBERTI S, TOMAS JM, BENEDI VJ, JACOBY GA. *In vivo* selection of porin-deficient mutants of *Klebsiella pneumoniae* with increased resistance to cefoxitin and expanded-spectrum cephalosporins. *Antimicrob Agents Chemother* 1996;40:342-8.
45. BLONDEAU JM, VAUGHAN D, LASKOWSKI R, BORSOS S, Canadian Antimicrobial Study Group. Susceptibility of Canadian isolates of *Haemophilus influenzae*, *Moraxella catarrhalis* and *Streptococcus pneumoniae* to oral antimicrobial agents. *Int J Antimicrob Agents* 2001;17:457-64.

Sažetak

ANTIBIOTSKA OSJETLJIVOST I PROIZVODNJA β -LAKTAMAZA KOD IZOLATA *MORAXELLA CATARRHALIS* IZ ZAGREBA, HRVATSKA*B. Bedenić i J. Vraneš*

Moraxella catarrhalis se je ranije smatrala komenzalom u respiracijskom traktu, ali se danas zna da je ona značajan respiracijski patogen. Proizvodnja β -laktamaze, prvi puta opisana 1977., javlja se sa sve većom učestalošću u mnogim zemljama svijeta. Dosad nije bilo izvještaja iz Hrvatske. Cilj ovoga istraživanja bio je ispitati osjetljivost na antibiotike i proizvodnju β -laktamaze u kliničkim izolatima *Moraxella catarrhalis* iz Hrvatske. Pedeset izolata *Moraxella catarrhalis* prikupljeno je iz različitih kliničkih uzoraka u Klinici za dječje bolesti Zagreb od 1990. do 1992. godine. Osjetljivost na antibiotike je određivana mikrodilucijskom metodom prema NCCLS. Proizvodnja β -laktamaza je utvrđivana metodom diska s kromogenim supstratom (nitrocefinski test). Supstratni profil je određivan biološkom metodom. β -Laktamaze su dokazane pomoću nitrocefinskog testa u svim sojevima. Učestalost β -laktamaza pozitivnih izolata *Moraxella catarrhalis* u ispitivanom razdoblju je iznosila 100%. Nije zapažena rezistencija na amoksicilin/klavulanat, cefaleksin, ceftibuten, tetraciklin, eritromicin, azitromicin i kloramfenikol. Aktivnost amoksicilina se je značajno pojačala u prisutnosti klavulanske kiseline u svim sojevima. Stariji cefalosporini su bili podjednako djelatni, dok je ceftibuten kao cefalosporin treće generacije imao značajno niže minimalne inhibicijske koncentracije u odnosu na starije generacije. Među ne β -laktamskim antibioticima tetraciklini i eritromicin su imali slične minimalne inhibicijske koncentracije. Azitromicin je imao jače inhibicijsko djelovanje od tetraciklina i eritromicina. Prema rezultatima našega istraživanja amoksicilin u kombinaciji s klavulanskom kiselinom bi bio antibiotik izbora za liječenje infekcija uzrokovanih sojevima *Moraxella catarrhalis* pozitivnim na β -laktamazu. Oralni cefalosporini, eritromicin, tetraciklini i azitromicin bi također mogli predstavljati moguću terapiju.

Ključne riječi: *Moraxella-Branhamella catarrhalis* – učinak lijekova; Protuinfekcijski lijekovi – farmakologija; Infekcije dišnog trakta – mikrobiologija; β -lactamiae – biosinteza; Hrvatska